PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Lehmann, F.M. ; Feicht, S. ; Helm, F.* ; Maurberger, A.* ; Ladinig, C. ; Zimber-Strobl, U. ; Kühn, R. ; Mautner, J.* ; Gerbitz, A.* ; Bornkamm, G.W.

Humanized c-Myc mouse.

PLoS ONE 7:e42021 (2012)
Verlagsversion Volltext DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background: A given tumor is usually dependent on the oncogene that is activated in the respective tumor entity. This phenomenon called oncogene addiction provides the rationale for attempts to target oncogene products in a therapeutic manner, be it by small molecules, by small interfering RNAs (siRNA) or by antigen-specific T cells. As the proto-oncogene product is required also for the function of normal cells, this raises the question whether there is a therapeutic window between the adverse effects of specific inhibitors or T cells to normal tissue that may limit their application, and their beneficial tumor-specific therapeutic action. To address this crucial question, suitable mouse strains need to be developed, that enable expression of the human proto-oncogene not only in tumor but also in normal cells. The aim of this work is to provide such a mouse strain for the human proto-oncogene product c-MYC. Principal Findings: We generated C57BL/6-derived embryonic stem cells that are transgenic for a humanized c-Myc gene and established a mouse strain (hc-Myc) that expresses human c-MYC instead of the murine ortholog. These transgenic animals harbor the humanized c-Myc gene integrated into the endogenous murine c-Myc locus. Despite the lack of the endogenous murine c-Myc gene, homozygous mice show a normal phenotype indicating that human c-MYC can replace its murine ortholog. Conclusions: The newly established hc-Myc mouse strain provides a model system to study in detail the adverse effects of therapies that target the human c-MYC protein. To mimic the clinical situation, hc-Myc mice may be cross-bred to mice that develop tumors due to overexpression of human c-MYC. With these double transgenic mice it will be possible to study simultaneously the therapeutic efficiency and adverse side effects of MYC-specific therapies in the same mouse.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.092
0.000
3
4
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter CANCER; MICE; GENE; DIFFERENTIATION; ANTISENSE; PROTEIN; CELLS; LYMPHOMAGENESIS; INACTIVATION; ONCOGENES
Sprache englisch
Veröffentlichungsjahr 2012
HGF-Berichtsjahr 2012
ISSN (print) / ISBN 1932-6203
Zeitschrift PLoS ONE
Quellenangaben Band: 7, Heft: 7, Seiten: , Artikelnummer: e42021 Supplement: ,
Verlag Public Library of Science (PLoS)
Verlagsort Lawrence, Kan.
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Molecular Immunology (IMI)
Research Unit Gene Vector (AGV)
Institute of Developmental Genetics (IDG)
Institute of Clinical Molecular Biology and Tumor Genetics (K.MOLBI)
CCG Pediatric Tumor Immunology (AGV-KPT)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30203 - Molecular Targets and Therapies
30204 - Cell Programming and Repair
Forschungsfeld(er) Immune Response and Infection
Genetics and Epidemiology
PSP-Element(e) G-501700-001
G-501500-003
G-500500-001
G-501400-001
G-520900-001
PubMed ID 22860051
DOI 10.1371/journal.pone.0042021
WOS ID WOS:000307045600053
Scopus ID 84864428299
Erfassungsdatum 2012-09-27
[➜Korrektur melden]